OneOme Announces New Specimen Option to Further Bring Its Powerful Pharmacogenomic Test Into Routine Clinical Care

MINNEAPOLIS (March 13, 2017) – OneOme today announced that healthcare providers now are able to order OneOme’s RightMed® pharmacogenomic test as part of an ordinary blood panel. Previously, the RightMed test was only available through a cheek swab. Making testing available using blood will further bring pharmacogenomic testing – the analysis of how a patient’s unique DNA affects their response to medications – into routine clinical care.

By offering a sample collection method that falls in line with the typical workflow for laboratory testing at many health systems, OneOme plans to drive increased adoption of the RightMed pharmacogenomic test.

“Learning how your genes might affect your response to medications is now as simple as getting a routine blood test or taking a cheek swab,” OneOme CEO Paul Owen said. “This is a major step toward bringing the power of pharmacogenomic testing into a patient’s routine healthcare regimen.”

An individual’s DNA largely predicts his or her response to medications. OneOme’s RightMed test analyzes those genes to help guide a physician toward a prescription that is best suited for that patient. The test helps make prescriptions personal and combats against adverse drug reactions, which are the fourth-leading cause of death in the United States.

This new blood testing option helps OneOme achieve its goal of helping patients select the most effective prescription for their unique DNA in a timely and cost-effective manner. The RightMed test, which costs $249, analyzes 22 genes to give physicians a better idea of how their patients will respond to more than 340 medications covering over 20 different clinical indications.

To ensure that healthcare providers can easily order the RightMed test and access results throughout a patient’s lifetime, OneOme is working to integrate test results into a patient’s electronic medical record (EMR). OneOme has also developed a platform for clients to generate an interpretative drug report using genotype or sequence data obtained elsewhere, all with the goal of better identifying which prescription medications may work best for individual patients.

Anyone can take the RightMed test, although some patients who may benefit most include: those who are taking some classes of medication, such as cardiovascular or psychiatric patients; those who are struggling with adverse drug reactions or medications that are not working; or those who are on multiple medications.

About OneOme
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit